Biocon Q2 preview: Biosimilars to drive growth; Generics likely to remain muted

Biocon's Q2 preview highlights strong biosimilar growth, while generics face challenges amid mixed sector performance ahead of November 11 results.

Biocon Biologics And Civica Team To Launch Private-Label Insulin Glargine In The U.S.

(n){if(!window.cnxel){window.cnxel={},window.cnxel.cmd=[];var t=n.createElement('iframe');t.src='javascript:false'; t.display='none',t.onload=function(){var ...
TipRanks on MSN

Novo Nordisk’s New Insulin Study: A Potential Game-Changer for Diabetes Management

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
Healio

20 years later, ‘a tremendous amount going on’ in management of cardiometabolic disease

In the treatment of cardiometabolic disease, much has changed in the past 20 years, especially with the emergence of novel ...